During this event, Cellevat3d® nanofiber microcarriers will be available for pre-order, with an official commercial launch scheduled for BIO-Europe in Stockholm from November 4-6, 2024.

Cellevate's technology aims to improve biomanufacturing productivity, ultimately making advanced therapies more accessible to patients.

The microcarriers are specifically designed for stirred tank bioreactors and support a range of applications, including gene therapy, pluripotent stem cell expansion, and vaccine production.

This pre-launch will provide early access to a new category of cell culture systems that are currently unavailable on the market.

For more information about the pre-launch and the technology, interested parties can visit Cellevate's website or contact CEO Laura Chirica directly via email.

Cellevate, a Swedish biotech company, is preparing to pre-launch the world's first nanofiber microcarrier for gene therapy at the CPHI Milan event, taking place from October 8-10, 2024.

These innovative microcarriers provide up to 60 times more surface area for cell growth compared to conventional systems, significantly enhancing yield and productivity in bioprocessing.

CEO Laura Chirica highlights that the nanofiber microcarriers are designed to mimic the human extracellular environment, effectively addressing the industry's challenges of low productivity and high manufacturing costs.